Fig. 6

Mutational characterization and risk groups for ARDEGs. A Enrichment of TME-infiltrating cells in two risk groups. B Differential outcomes of TIDE scores and MSI scores. C Differences in response to the four immunotherapies in the IMvigor 210 cohort (using the Kruskal–Wallis H test). D KM survival indicated that the two distinct risk groups were notably related to OS. E Different scores of tumour stemness index. F Sensitivity to differential chemotherapeutic drugs